9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Estimated reading time: < 1 min

Condition: Advanced Solid Tumors or Lymphomas

Estimated Enrollment: 300

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle,  Maximum tolerated dose (MTD) of CA-170,  Recommended Phase 2 Dose (RP2D) of CA-170, Pharmacokinetic (PK) Profile of CA-170

Interventions: CA-170,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 2020

Completion Date: January 2020

Last  Posted Date: May 6, 2019

Location: University of California San Francisco, San Francisco, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02812875

Was this article helpful?
Dislike 0